India, Aug. 24 -- VERAXA Biotech AG (VRXA) and Secarna Pharmaceuticals GmbH & Co. KG announced initial positive results from in vitro studies under their strategic research collaboration to develop antibody-oligonucleotide conjugates (AOCs) for the treatment of autoimmune and chronic immune diseases.
AOCs combine the specificity of monoclonal antibodies with the functional versatility of oligonucleotides.
As part of the collaboration, Secarna leverages its proprietary, AI-empowered OligoCreator discovery and development platform to identify promising oligonucleotide candidates, applying antisense oligonucleotides (ASOs) and siRNA strategies, while VERAXA will leverage its click-chemistry conjugation platform to design and generate AOCs.
...